Why is Medicamen Biotec falling/rising?

As of 19-Sep, Medicamen Biotech Ltd is currently priced at 334.00, with no change in price (0.00%). The stock has recently hit a new 52-week low of Rs. 326 and has underperformed its sector by 0.27%. Over the past week, the stock has declined by 3.19%, and it has shown a significant year-to-date drop of 34.41%. Despite a rise in investor participation, with delivery volume increasing by 10.17% against the 5-day average, the stock is trading below all key moving averages, indicating a bearish trend. The company has a low debt-to-equity ratio of 0.09, but its operating profit has decreased at an annual rate of 12.66% over the last five years, contributing to a negative outlook.
In the broader market context, the Sensex has gained 0.88% over the past week, contrasting sharply with Medicamen Biotech's decline. The stock has consistently underperformed against the benchmark, generating a return of -25.94% over the last year while the Sensex has remained nearly flat at -0.67%. This consistent underperformance, coupled with flat results in the latest financial reports and a low return on capital employed (ROCE) of 5.30%, suggests that investor sentiment is weak, leading to the stock's downward movement. Overall, the combination of poor long-term growth prospects and recent negative performance metrics has resulted in a lack of confidence among investors.